Clinical Data Inc

Clinical Data — BMO Capital Markets Focus On Healthcare Conference 2008

33 slides from Clinical Data's conference presentation, Aug 5, 2008

  1. Slide 1: BMO Capital Markets Focus On Healthcare Conference

    Slide 1: BMO Capital Markets Focus On Healthcare Conference

    1 BMO Capital Markets Focus On Healthcare Conference August 5, 2008 NASDAQ: CLDA

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    1 Forward-Looking Statements This presentation contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements

  3. Slide 3: Corporate Snapshot

    Slide 3: Corporate Snapshot

    Corporate Snapshot Headquarters Newton, MA NASDAQ CLDA 52 Week Price Range $12.74 to $28.90* Shares Outstanding 21.14 million* Market Cap $348 million* *As of market close on August 4, 2008 3

  4. Slide 4: Clinical Data - Key Drivers

    Slide 4: Clinical Data - Key Drivers

    Clinical Data - Key Drivers Emerging leader in personalized therapeutics and diagnostics Growing therapeutics pipeline with late stage compounds Proprietary genetic and pharmacogenetic testing business demonstrating rapid growth 4

  5. Slide 5: Our Businesses

    Slide 5: Our Businesses

    Our Businesses Comprehensive Genomics Services Targeted Therapeutics Mainstream Clinical Care Patients Providers Payers Clinical Trials and Research Biotech/ Pharmaceutical Companies Proprietary Genetic and Pharmacogenetic Tests 5

  6. Slide 6: Comprehensive Genomics Services, Targeted Therapeutics, Mainstream Clinical Care

    Slide 6: Comprehensive Genomics Services, Targeted Therapeutics, Mainstream Clinical Care

    Comprehensive Genomics Services Targeted Therapeutics Mainstream Clinical Care Patients Providers Payers Clinical Trials and Research Biotech/ Pharmaceutical Companies Proprietary Genetic and Pharmacogenetic Tests 6

  7. Slide 7: Clinical Data Acquires Adenosine Therapeutics

    Slide 7: Clinical Data Acquires Adenosine Therapeutics

    The addition of Adenosine Therapeutics' highly selective adenosine receptor modulators to Clinical Data's drug development and biomarker expertise will lead to therapeutic and diagnostic products with significant clinical and economic impact. Clinical Data Acquires Adenosine Therapeutics

  8. Slide 8: Primary Transaction Value Drivers

    Slide 8: Primary Transaction Value Drivers

    Expands PGxHealth's therapeutics pipeline: cardiology, diabetes, inflammatory disease, sickle cell anemia Early-stage biomarker strategy: opportunity to incorporate targeted strategy from pre-clinical and early clinical stages Two molecules optioned for out-licensing: ATL844 for diabetes and asthma

  9. Slide 9: Primary Transaction Value Drivers: Stedivaze

    Slide 9: Primary Transaction Value Drivers: Stedivaze

    Stedivaze(tm) A pharmacologic stress agent in cardiac perfusion imaging Poised to enter Phase 3 testing, initiating first half 2009 Possible best-in-class attributes 2007 sales of leading product ~$330 million Synergistic with Clinical Data's existing cardiology sales force Primary Transaction Value

  10. Slide 10: Purchase Is Non-Dilutive

    Slide 10: Purchase Is Non-Dilutive

    $11 million cash at closing $22 million 5-year promissory note 32-month note of $3.2 million (transfer of VC debt) Up to $30 million contingent on milestones $5 million on first FDA approval of an Adenosine Therapeutics compound $10 million on achievement of $100 million gross sales of any Adenosine

  11. Slide 11: Therapeutics and biomarkers of drug response and disease

    Slide 11: Therapeutics and biomarkers of drug response and disease

    Therapeutics and biomarkers of drug response and disease Therapeutics Genetic and Pharmacogenetic Tests Targeted Therapeutics and PGx Tests Foundation Intellectual Property Developing Value Tools for Clinical Care 11

  12. Slide 12: Diagnostic Products and Pipeline

    Slide 12: Diagnostic Products and Pipeline

    Diagnostic Products and Pipeline In Development Commercially Available Familion Tests Familion Tests Familion Tests PGxPredict Tests PGxPredict Tests PGxPredict Tests PGxPredict:trastuzumab PGxPredict:cetuximab PGxPredict test: CNS PGxPredict test: RA PGxPredict test: diabetes Est. Relaunch Q4 2008

  13. Slide 13: Therapeutics Pipeline

    Slide 13: Therapeutics Pipeline

    Therapeutics Pipeline Lead Discovery Preclinical Phase I Phase II Phase III NDA Marketed Vilazodone Apadenoson StedivazeTM Cardiac Imaging Acute Inflammation ATL1222-Acute Inflammation ATL844-Diabetes ATL844-Asthma ATL908-Ophthalmic Other Potential Applications: COPD DES/MI Chronic Inflammation Pain

  14. Slide 14: Therapeutics Pipeline

    Slide 14: Therapeutics Pipeline

    Therapeutics Pipeline Lead Discovery Preclinical Phase I Phase II Phase III NDA Marketed Vilazodone Apadenoson StedivazeTM Cardiac Imaging Acute Inflammation ATL1222-Acute Inflammation ATL844-Diabetes ATL844-Asthma ATL908-Ophthalmic Other Potential Applications: COPD DES/MI Chronic Inflammation Pain

  15. Slide 15: Vilazodone Overview

    Slide 15: Vilazodone Overview

    Vilazodone Overview Genetically guided, dual-acting serotonergic in development for the treatment of depression $12 billion market (U.S.); 17 million Americans Status of development Positive results from first Phase 3 study effective vs. placebo (p = .001) side effect profile similar to that of SSRI

  16. Slide 16: Proprietary Biomarker Identifies 30% of Patients with Higher Response

    Slide 16: Proprietary Biomarker Identifies 30% of Patients with Higher Response

    Proprietary Biomarker Identifies 30% of the Patients with a Higher than Average Response to Vilazodone Least square means of observed MADRS total score by week for Biomarker Vilazodone-treated patients who are marker positive have twice the change in MADRS at week 8 compared to the overall populatio

  17. Slide 17: Therapeutics Pipeline

    Slide 17: Therapeutics Pipeline

    Therapeutics Pipeline Lead Discovery Preclinical Phase I Phase II Phase III NDA Marketed Vilazodone Apadenoson StedivazeTM Cardiac Imaging Acute Inflammation ATL1222-Acute Inflammation ATL844-Diabetes ATL844-Asthma ATL908-Ophthalmic Other Potential Applications: COPD DES/MI Chronic Inflammation Pain

  18. Slide 18: Stedivaze Overview

    Slide 18: Stedivaze Overview

    StedivazeTM Overview Selective A2a adenosine receptor agonist for use as a pharmacologic stress agent in cardiac perfusion imaging studies Development Phase 2 data show potential best-in-class attributes Concordance with market leader (efficacy) AE profile suggests improved tolerability over market

  19. Slide 19: Market Needs: Pharmacologic Stress Agents

    Slide 19: Market Needs: Pharmacologic Stress Agents

    Diagnostic accuracy Tolerability Ease of use Bolus dosing No adjustment for body weight Rapid onset and offset Market Needs: Pharmacologic Stress Agents

  20. Slide 20: Stedivaze vs. Market Needs: Pharmacologic Stress Agents

    Slide 20: Stedivaze vs. Market Needs: Pharmacologic Stress Agents

    Stedivaze: Diagnostic accuracy: concordance with Adenoscan(r) Tolerability: potential for best-in-class SE profile Ease of use: planned for commercial product Bolus dosing No adjustment for body weight Rapid onset and offset: supported by PK Market Needs: Pharmacologic Stress Agents

  21. Slide 21: Stedivaze Phase 2 Trial Adverse Events

    Slide 21: Stedivaze Phase 2 Trial Adverse Events

    Stedivaze Phase 2 Trial Adverse Events Stedivaze Phase 2 Trial Adverse Events Stedivaze Phase 2 Trial Adverse Events Stedivaze Phase 2 Trial Adverse Events 1.0 ^g/kg 2.0 ^g/kg Adenoscan Total Safety Subjects 61 63 124 No of Subjects with AEs 22 (36%) 43 (68%) 105 (85%) Most Frequent Complaints Dyspn

  22. Slide 22: Stedivaze Development Milestones

    Slide 22: Stedivaze Development Milestones

    Stedivaze Development Milestones End-of-Phase-2 meeting with FDA in coming months Commence two Phase 3 trials 1H2009 Streamlined development timelines and costs pending FDA review

  23. Slide 23: Therapeutics Pipeline

    Slide 23: Therapeutics Pipeline

    Therapeutics Pipeline Lead Discovery Preclinical Phase I Phase II Phase III NDA Marketed Vilazodone Apadenoson StedivazeTM Cardiac Imaging Acute Inflammation ATL1222-Acute Inflammation ATL844-Diabetes ATL844-Asthma ATL908-Ophthalmic Other Potential Applications: COPD DES/MI Chronic Inflammation Pain

  24. Slide 24: Strategic Opportunity In Diabetes

    Slide 24: Strategic Opportunity In Diabetes

    Each company brings expertise and IP related to diabetes ATL844 is in preclinical development for the treatment of T2D Clinical Data is pursuing a pharmacogenetic biomarker of response to treatment of T2D, a multigenic disease Strategic opportunity to leverage existing expertise of both companies to

  25. Slide 25: Potential Indications Based on Adenosine Receptor Subtypes

    Slide 25: Potential Indications Based on Adenosine Receptor Subtypes

    Potential Indications Based on Adenosine Receptor Subtypes A2A Agonists Acute Inflammation Chronic Inflammation A2B Antagonists Asthma Diabetes Inflammatory Bowel Disease A2A Antagonists (centrally active) ADHD Drug Addiction Parkinson's Disease A2A Antagonists (peripherally active) Cancer

  26. Slide 26: Comprehensive Genomics Services, Targeted Therapeutics, Mainstream Clinical Care

    Slide 26: Comprehensive Genomics Services, Targeted Therapeutics, Mainstream Clinical Care

    Comprehensive Genomics Services Targeted Therapeutics Mainstream Clinical Care Patients Providers Payers Clinical Trials and Research Biotech/ Pharmaceutical Companies Proprietary Genetic and Pharmacogenetic Tests 26

  27. Slide 27: Cogenics Overview

    Slide 27: Cogenics Overview

    Overview Sequencing, gene expression, genotyping and other molecular services worldwide Broad customer base, U.S. and international, including most of the top 20 pharmaceutical companies Dovetails with next-generation genomic testing for diagnostics and targeted drug therapy (companion diagnostics R

  28. Slide 28: Broadest genomics services menu in the industry

    Slide 28: Broadest genomics services menu in the industry

    Broadest genomics services menu in the industry: Sequencing ABI 3730 Roche 454 GS FLX (new) Genotyping RFLP Mapping Sequenom Luminex Illumina iScanTM System Agilent Microarray aCGH miRNA Affymetrix Microarray Whole Genome Association DNA Analysis DME-T Algynomics Pain Chip Gene Expression Analysis M

  29. Slide 29: From Targeted Science

    Slide 29: From Targeted Science

    From Targeted Science Healthcar

  30. Slide 30: Fiscal 2008 Summary

    Slide 30: Fiscal 2008 Summary

    Fiscal 2008 Summary (as of March 31, 2008) Revenue from continuing operations was up 20% PGxHealth revenue grew 33%; tests sales grew 41% Cogenics revenue grew 18% Cash burned for the first 9 months was ~$19.0 million; $27.0 million for the full year; average quarterly burn from operations was ~$7.0

  31. Slide 31: Fiscal Year Revenue Growth

    Slide 31: Fiscal Year Revenue Growth

    Fiscal Year Revenue Growth $24.4 $20.6 $2.7 $29.4 $24.3 $4.6 FY '07 FY '08 $1.1 $0.5 31

  32. Slide 32: Fiscal Year 2009 Objectives

    Slide 32: Fiscal Year 2009 Objectives

    Fiscal Year 2009 Objectives Advance clinical development programs: Vilazodone: Phase 3 Stedivaze: Phase 3 Other A2A/A2B compounds: Preclinical, Phase 1, Phase 2 Other biomarker discovery, PGx tests Drive adoption and sales of the Company's proprietary genetic and pharmacogenetic tests Continue to ac

  33. Slide 33: Thank You

    Slide 33: Thank You

    33 Thank You www.clda.com Investor inquiries: Dahlia Bailey 415-896-5862

Source: SEC EDGAR · 8-K filed Aug 5, 2008

More decks from Clinical Data Inc